
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is poised for success as their selective oral immunology therapies show promise in treating chronic inflammatory and autoimmune diseases. With a strong pipeline of small molecule products in development and potential indication expansions in multiple sclerosis, the company is well-positioned for growth. The recent positive Phase 2 trial results for vidofludimus calcium in relapsing-remitting multiple sclerosis bode well for the ongoing Phase 3 ENSURE program, with promising efficacy data on relapse and confirmed disability progression. Investors should closely monitor the topline results from the ENSURE trials, as well as the potential launch of a Phase 3 program for primary progressive multiple sclerosis later in 2026.
Bears say
Immunic is a clinical-stage biopharmaceutical company operating in one segment. However, their small molecule products are still in the early stages of development and have no guarantee of success, and the recent 1-for-10 reverse stock split and potential follow-on financing activity create additional technical and dilution risks. Meanwhile, current oral therapies for RMS only target inflammation and relapses, leaving a gap in addressing disability progression. These factors, along with potential market share risk, contribute to the negative outlook for the stock.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares